Polymyxin B (sulfate): A Benchmark Polypeptide Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate) is a crystalline antibiotic mixture targeting multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa (APExBIO, product page). It functions by disrupting bacterial membranes as a cationic detergent, exhibiting rapid bactericidal action and immune-modulatory properties (Sardar et al., 2025, DOI). In vitro, it induces dendritic cell maturation and activates ERK1/2 and NF-κB signaling. In vivo, it decreases bacterial burden and improves survival in bacteremia models. Its use is limited by nephro- and neurotoxicity risks, necessitating precise workflow integration and awareness of its limitations.

Biological Rationale

Polymyxin B (sulfate) is a polypeptide antibiotic derived from Bacillus polymyxa strains, primarily composed of polymyxins B1 and B2. It is specifically indicated for infections caused by multidrug-resistant Gram-negative organisms, most notably Pseudomonas aeruginosa and Acinetobacter baumannii (APExBIO). The prevalence of resistance among Gram-negative pathogens has renewed clinical and research interest in this compound. Its mechanism uniquely targets the outer membrane of Gram-negative bacteria, making it a cornerstone for both therapeutic and experimental approaches. Polymyxin B (sulfate) also exhibits ancillary activity against some fungi and Gram-positive bacteria, though with less potency (see detailed comparative review; this article extends the discussion with immune and microbiome context).

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B acts as a cationic detergent. It binds to the lipid A component of lipopolysaccharides (LPS) in the outer membrane of Gram-negative bacteria. The binding displaces divalent cations (Ca²⁺, Mg²⁺) that stabilize the membrane, resulting in increased permeability and cell death. The molecular weight of the compound is 1301.6 Da, and its chemical formula is C₅₆H₉₈N₁₆O₁₃·H₂SO₄. It is soluble up to 2 mg/ml in phosphate-buffered saline (PBS, pH 7.2) at 20°C (APExBIO). In immune cells, such as human dendritic cells, Polymyxin B upregulates co-stimulatory molecules (CD86, HLA class I/II) and activates ERK1/2 and IκB-α/NF-κB intracellular signaling pathways (see context for immunomodulation; this article clarifies mechanistic specificity).

Evidence & Benchmarks

• Polymyxin B (sulfate) rapidly kills multidrug-resistant Gram-negative bacteria in vitro, with >95% purity confirmed by HPLC analysis (APExBIO).
• In mouse bacteremia models, Polymyxin B improves survival rates in a dose-dependent manner and significantly reduces bacterial load within 6 hours post-infection (Sardar et al., 2025, DOI).
• In vitro, Polymyxin B induces maturation of human dendritic cells, as measured by upregulation of CD86 and HLA class I/II molecules (Sardar et al., 2025, DOI).
• Polymyxin B directly disrupts LPS-mediated TLR4 signaling, modulating immune responses in the context of Gram-negative bacterial infection (DOI).
• APExBIO's Polymyxin B (sulfate) C3090 kit supports robust and reproducible workflows for cell viability and proliferation assays (see internal guidance; this article updates with new immune and microbiome findings).

Applications, Limits & Misconceptions

Polymyxin B (sulfate) is utilized in research and clinical settings to treat infections caused by carbapenem-resistant Enterobacteriaceae, P. aeruginosa, and A. baumannii. It is also integral in sepsis and bacteremia mouse models, immune cell activation studies, and as a tool for dissecting LPS structure-function biology in translational research (broader translational perspective; this article provides updated immune and microbiome benchmarks). The compound is not effective against most Gram-positive bacteria or anaerobes. Its use is limited by potential nephrotoxicity and neurotoxicity, especially at higher or prolonged dosing. Polymyxin B does not neutralize all LPS structures equally; hexa-acylated LPS is more potently targeted, while hypo-acylated forms may antagonize immune activation (DOI).

Common Pitfalls or Misconceptions

• Polymyxin B (sulfate) is not effective against Gram-positive bacteria or fungi at clinically relevant concentrations.
• It does not neutralize all LPS structures equally; hypo-acylated LPS may escape its action (Sardar et al., 2025).
• Prolonged or high-dose exposure may lead to nephrotoxicity and neurotoxicity—use with careful monitoring and according to protocol.
• Stability of solutions is limited; fresh preparation is recommended for critical assays (APExBIO).
• Research use does not substitute for clinical therapy decisions; always consult up-to-date guidelines.

Workflow Integration & Parameters

Polymyxin B (sulfate) is supplied as a crystalline powder (SKU C3090) by APExBIO, with ≥95% purity. Reconstitute at up to 2 mg/ml in PBS, pH 7.2, at room temperature. Store powder at –20°C; use solutions immediately or within 1–2 days for maximum activity. Typical in vitro concentrations range from 0.5–10 μg/ml, depending on assay and cell type. For dendritic cell maturation assays, 1 μg/ml for 18–24 h is standard. In bacteremia mouse models, dosing regimens should be titrated for survival endpoints. Always include appropriate controls, especially when probing LPS-TLR4 signaling or immune readouts. For further scenario-driven integration, see this practical guidance; this article clarifies immune-microbiome research boundaries.

Conclusion & Outlook

Polymyxin B (sulfate) remains an essential research tool and therapeutic candidate against multidrug-resistant Gram-negative bacteria. Its unique mechanism, rapid bactericidal action, and immune-modulatory properties support a broad range of applications, from classical microbiology to modern immunotherapy and microbiome research. However, careful attention to LPS structural diversity, toxicity risks, and workflow parameters is critical for valid, reproducible results. As new insights emerge on the interplay of LPS structure, host immunity, and antibiotic action (Sardar et al., 2025), Polymyxin B (sulfate) will remain central to the evolving research and clinical landscape.